Mineralys Therapeutics’ $40 Million Series A Funding Round

Latham & Watkins LLP represented Mineralys Therapeutics, Inc. in the transaction.

Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific, completed a US$40 million Series A funding round. The financing was led by HBM Healthcare Investments and Samsara BioCapital with founding investment firm Catalys Pacific and Adam Street Partners participating in the round.

The company also announced that the US Food and Drug Administration has accepted their Investigational New Drug Application for an investigational compound MLS-101, an aldosterone synthase inhibitor, for the treatment of hypertension. The financing will enable Mineralys to complete its Phase 2 proof-of-concept study for MLS-101, as well as preparatory work for its pivotal trial development program. 

Latham & Watkins LLP represented Mineralys Therapeutics, Inc. in the financing with a San Diego-based deal team led by partner Cheston Larson (Picture) and counsel Chris Geissinger, with associate Evan Youngstrom.

Involved fees earner: Christopher Geissinger – Latham & Watkins; Cheston Larson – Latham & Watkins; Evan Youngstrom – Latham & Watkins;

Law Firms: Latham & Watkins;

Clients: Mineralys Therapeutics;

Author: Martina Bellini